Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Astrazeneca Ord Shs AZNCF

AstraZeneca PLC is a science-led biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza... see more

Recent & Breaking News (OTCPK:AZNCF)

Probiodrug Transfers its CDK9 Inhibitor Program to AstraZeneca

Business Wire January 3, 2014

Obesity Stock Plays Standing Out from the Crowd

Accesswire December 20, 2013

FDA Advisory Committee Recommends the Investigational SGLT2 Inhibitor Dapagliflozin for the Treatment of Type 2 Diabetes in Adults

Business Wire December 12, 2013

FDA Advisory Committee Votes on Investigational Medicine Metreleptin

Business Wire December 11, 2013

Xigduo(TM) (dapagliflozin and metformin hydrochloride) Receives Positive CHMP Opinion in the European Union for the Treatment of Type 2 Diabetes

Business Wire November 22, 2013

NHANES Analyses Reinforce the Need for Education to Help Increased Risk Dyslipidemic Patients Aggressively Treat Their Cholesterol

Business Wire November 20, 2013

SumTotal Talent Expansion Applications Enable High-Performance Organization at City of Danville

Business Wire November 18, 2013

AstraZeneca Announces Initiation of Two Additional Global Studies with Brilinta (Ticagrelor)

Business Wire November 14, 2013

AstraZeneca Applauds the Release of New U.S. Guideline for Management of Blood Cholesterol

Business Wire November 12, 2013

COPD on the Rise and Many Don't Recognize the Symptoms

PR Newswire November 11, 2013

Martin Engineering Chooses SumTotal Talent Expansion Suite to Develop and Retain Employees

Business Wire October 28, 2013

A Large, Observational Study of Common Gout Treatment Allopurinol Shows Less Than Half of Patients Reach Recommended Treatment Goal

Business Wire October 28, 2013

Five Star Equities Issues New Research Reports on AZN, DPZ, DXCM and JNJ

Accesswire October 23, 2013

Patterson Companies Chooses SumTotal to Develop Employees with Social and Mobile Technologies

Business Wire October 21, 2013

SumTotal, USA Funds Win Gold Brandon Hall Group Excellence Award

Business Wire October 18, 2013

SumTotal Announces SumTotal Talent Expansion Suite Integration with Salesforce Identity

Business Wire October 15, 2013

AstraZeneca Announces New Safety Data For Naloxegol In Patients with Opioid-Induced Constipation

Business Wire October 14, 2013

SumTotal's Talent Expansion Suite Delivers Industry's First Context-Aware User Experience for HR

Business Wire October 7, 2013

New Interactive Tools Empower Women to Express Selves, Raise Awareness on October 13 - Metastatic Breast Cancer Awareness Day

PR Newswire October 7, 2013

SumTotal elixHR(TM) Platform Named Top HR Product of 2013 by Human Resource Executive Magazine Editors

Business Wire October 1, 2013